# Project 2: Characterizing and overcoming failure to respond to PD-1 blockade therapy

> **NIH NIH P01** · UNIVERSITY OF WASHINGTON · 2022 · $407,751

## Abstract

SUMMARY PROJECT 2: Merkel cell carcinoma (MCC) is a rare but often deadly skin cancer caused by the Merkel
cell polyomavirus (MCPyV) in 80% of cases. MCPyV T-antigen oncoproteins are persistently expressed in virus-
positive MCCs (VP-MCC), while remarkably high numbers of UV-induced neoantigens are detected in virus-negative
MCCs (VN-MCC), suggesting both MCC subsets harbor immunogenic epitopes. Based on our early studies of the
immune response in MCC, our group led multiple clinical trials that have recently changed the standard of care for this
cancer. PD-1 blockade has yielded high response rates in MCC as compared with other solid tumors, and markedly
improved outcomes compared to cytotoxic chemotherapy, the only prior option for advanced MCC. Unfortunately,
40% of MCC patients do not initially benefit from PD-1 blockade and ~20% of responders later develop acquired
resistance. Consequently, there is an urgent need to identify therapeutically targetable mechanisms of resistance.
 In this proposal, we seek to identify reversible mechanisms of resistance to PD-1 blockade by analyzing three
critical components across this Project: Aim 1: MCC-specific T lymphocytes. We will determine whether T cell
infiltration patterns into tumors, T cell clonal diversity, or dysfunctional status are associated with failure to respond to
PD-1 blockade therapy. Aim 2: MCC tumor cells. We will determine whether MCC cell intrinsic immune characteristics
including expression of additional checkpoint molecules or impaired antigenicity are associated with
response/resistance to PD-1 blockade. Aim 3: MCC innate immunity. We will study the correlation between
intratumoral infiltration of two innate immune cell types (macrophages and NK cells) and MCC outcome to determine
whether therapeutic intervention with innate immune stimulation can augment MCC adaptive immunity.
 Notably, we have made several significant advances since our May 2017 submission which will greatly increase
our ability to identify and test the functional relevance of immune mechanisms mediating resistance to PD-1 blockade.
These advances include: (1) A scRNAseq workflow which can be performed on small amounts (1 core biopsy) of
cryopreserved material, enabling careful collection and selection of highly informative patient samples and improved
depth of analysis; (2) MCC tumor expansion in patient derived xenograft (PDX) mice for subsequent use in functional
assays including a slice-culture/explant system. Unbiased approaches including scRNAseq, will be initially employed
to optimize our capacity to identify novel and significant immune evasion mechanisms, as we have demonstrated
since the time of our initial submission. Under the guidance of our External and Internal Advisory Boards, we will then
select the pathways most strongly associated with PD-1 blockade response. These immune evasion pathways will be
studied in a larger number of patients and their functional significance/reversibility will be de...

## Key facts

- **NIH application ID:** 10380818
- **Project number:** 5P01CA225517-04
- **Recipient organization:** UNIVERSITY OF WASHINGTON
- **Principal Investigator:** PAUL NGHIEM
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $407,751
- **Award type:** 5
- **Project period:** 2019-04-04 → 2024-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10380818

## Citation

> US National Institutes of Health, RePORTER application 10380818, Project 2: Characterizing and overcoming failure to respond to PD-1 blockade therapy (5P01CA225517-04). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10380818. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*